Information, Community and Research Funding

The mission of The EHE Foundation is to seek treatments and a cure for Epithelioid Hemangioendothelioma (EHE) by increasing awareness, pursuing scientific research, advocating for and supporting EHE patients, and bridging information between researchers, providers and patients.

HOW TO FIGHT EHE

CONNECT

Signup for our email newsletter below to hear about the latest research, fundraisers and events. Follow us on Facebook. Don’t forget to hit that Like button!

DONATE

Donate and encourage others to donate as well. Attend and support one of the fundraising events held each year. To view the funding needed see our Current Research Page

SHARE

Share the EHE Foundation with the world. Let them know that we are here and that we need funding to fight EHE. Tell them your story and encourage them to help.

IMPORTANT EHE NEWS & TRIALS

Trametinib Trial

Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That Is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery.

ClinicalTrials.gov Identifier:  NCT03148275

For the last several years Dr.Brian Rubin has been working on unlocking genetic driving mechanism behind EHE progression. His work resulted in identification of a pathway directly involved in supporting of EHE genetic malfunction .During the Lab experiments, Dr Rubin was able to disrupt this pathway with MEK inhibitor.

The clinical trial uses MEK inhibitor Mekinist. The purpose of the study to verify that what Dr.Rubin observed in his Lab actually translates in clinical effect in EHE patients. It is a multi institutional study which makes it very easy for enrolment in different parts of the country. You can see more information using following link.

https://clinicaltrials.gov/ct2/show/NCT03148275

Axitinib and Pembrolizumab Trial

Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas

ClinicalTrials.gov Identifier:  NCT02636725

This is the only immunotherapy study currently listing EHE as designated sarcoma. Immunotherapy drug Pembrolizumab( Keytruda) is combined with anti angiogenic drug Axitinib.Both groups of drugs showed some effect in EHE patients. Their combination already presented synergetic effect in other cancers. Immunotherapy is gaining momentum and Dr. Breelyn Wilky from Sylvester Cancer Center in Miami is one of the leading immuno oncologists in sarcoma. She is a Primary Investigator in this trial. The study is conducted only in Miami. You can see more information using following link.

https://clinicaltrials.gov/ct2/show/NCT02636725

FEATURED FIGHTERS

Justin Bryan Featured

Justin Bryan is One Tuff Dude

In October of 2015, Justin Bryan endured a 10-day trek up 19,341 feet of elevation as he scaled the peak of Mount Kilimanjaro in Tanzania. Not too shabby for a man who was told 12…

Learn More
Mandy and Devin O'Connor

Mandy O’Connor

Mandy O’Connor, a York native, Penn State graduate, and THON participant, fought Epithelioid Hemangioendothelioma (EHE) for more than a decade. EHE is a rare and often deadly vascular sarcoma (cancer) that largely affects adolescents and…

Learn More
Ava Featured Image

Ava’s Story

Ava is an eight year old girl from Langhorne, PA, where Sesame Place is located. We are about 25 miles from Center City Philadelphia. Ava loves swimming and going to Sesame Place, since it is…

Learn More